- Home
- GITS vs RLMD Comparison
GITS vs RLMD Comparison
Compare GITS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- RLMD
- Stock Information
- Founded
- GITS 2018
- RLMD 2004
- Country
- GITS South Korea
- RLMD United States
- Employees
- GITS N/A
- RLMD N/A
- Industry
- GITS
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- RLMD Health Care
- Exchange
- GITS Nasdaq
- RLMD Nasdaq
- Market Cap
- GITS 11.6M
- RLMD 11.5M
- IPO Year
- GITS N/A
- RLMD N/A
- Fundamental
- Price
- GITS $2.38
- RLMD $0.30
- Analyst Decision
- GITS
- RLMD Hold
- Analyst Count
- GITS 0
- RLMD 4
- Target Price
- GITS N/A
- RLMD $4.25
- AVG Volume (30 Days)
- GITS 279.7K
- RLMD 2.1M
- Earning Date
- GITS 11-20-2024
- RLMD 03-18-2025
- Dividend Yield
- GITS N/A
- RLMD N/A
- EPS Growth
- GITS N/A
- RLMD N/A
- EPS
- GITS N/A
- RLMD N/A
- Revenue
- GITS N/A
- RLMD N/A
- Revenue This Year
- GITS N/A
- RLMD N/A
- Revenue Next Year
- GITS N/A
- RLMD N/A
- P/E Ratio
- GITS N/A
- RLMD N/A
- Revenue Growth
- GITS 85.47
- RLMD N/A
- 52 Week Low
- GITS $0.10
- RLMD $0.28
- 52 Week High
- GITS $5.06
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- GITS N/A
- RLMD 30.81
- Support Level
- GITS N/A
- RLMD $0.28
- Resistance Level
- GITS N/A
- RLMD $0.36
- Average True Range (ATR)
- GITS 0.00
- RLMD 0.04
- MACD
- GITS 0.00
- RLMD 0.02
- Stochastic Oscillator
- GITS 0.00
- RLMD 7.21
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.